| 1 |
Hurlburt KJ, McMahon BJ, Deubner H, et al.Prevalence of autoimmune liver disease in Alaska Native[J]. Am J Gastroenterol, 2002, 97(9): 2402-2407.
|
| 2 |
Kim BH, Choi HY, Ki M, et al.Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea[J]. PLoS One, 2017, 12(8): e0182391.
|
| 3 |
Aizawa Y, Hokari A. Autoimmune hepatitis: current challenges and future prospects[J]. Clin Exp Gastroenterol, 2017, 10: 9-18.
|
| 4 |
俞立飞，金洁．自身免疫性肝炎中Th17/Treg细胞平衡变化的研究进展[J]．中国卫生检验杂志，2016(9): 1366-1368.
|
| 5 |
Abe M, Mashiba T, Zeniya M, et al.Present status of autoimmune hepatitis in Japan: a nationwide survey[J]. J Gastroenterol, 2011, 46(9): 1136-1141.
|
| 6 |
van Gerven NM, de Boer YS, Mulder CJ, et al.Auto immune hepatitis[J]. World J Gastroenterol, 2016, 22(19): 4651-4661.
|
| 7 |
Sahebjam F, Vierling JM.Autoimmune hepatitis[J]. Front Med, 2015, 9(2): 187-219.
|
| 8 |
Czaja AJ.Performance parameters of the conventional serological markers for autoimmune hepatitis[J]. Dig Dis Sci, 2011, 56(2): 545-554.
|
| 9 |
Manns MP, Czaja AJ, Gorham JD, et al.Diagnosis and management of autoimmune hepatitis[J]. Hepatology, 2010, 51(6): 2193-2213.
|
| 10 |
Yasui S, Fujiwara K, Yonemitsu Y, et al.Clinicopathological features of severe and fulminant forms of autoimmune hepatitis[J]. J Gastroenterol, 2011, 46(3): 378-390.
|
| 11 |
Czaja AJ.Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions[J]. Gut Liver, 2016, 10(2): 177-203.
|
| 12 |
Weiler-Normann C, Schramm C, Quaas A, et al.Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis[J]. J Hepatol, 2013, 58(3): 529-534.
|
| 13 |
Manns MP, Woynarowski M, Kreisel W, et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J]. Gastroenterology, 2010, 139(4): 1198-206.
|
| 14 |
Baven-Pronk AMC, Coenraad MJ, van Buuren HR, et al.The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther, 2011, 34(3): 335-343.
|
| 15 |
Zachou K, Gatselis NK, Arvaniti P, et al.A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2016, 43(10): 1035-1047.
|
| 16 |
Czaja AJ.Autoimmune hepatitis: focusing on treatments other than steroids[J]. Can J Gastroenterol, 2012, 26(9): 615-620.
|
| 17 |
Nasseri-Moghaddam S, Nikfam S, Karimian S, et al.Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis: Interim Analysis Report of a Randomized Controlled Trial[J]. Middle East J Dig Dis, 2013, 5(4): 193-200.
|
| 18 |
Than NN, Wiegard C, Weiler-Normann C, et al.Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy[J]. Scand J Gastroenterol, 2016, 51(3): 329-336.
|
| 19 |
D′Agostino D, Costaguta A, álvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab[J]Pediatrics, 2013, 132(2): e526-e530.
|
| 20 |
Rodrigues S, Lopes S, Magro F, et al.Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases[J]. World J Gastroenterol, 2015, 21(24): 7584-7588.
|